Stocks › A › ABUS

Arbutus Biopharma Corporation (ABUS) — Earnings Call X-Ray

Our AI read all 32 of ABUS's earnings calls (2017–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q3 2024 · sign up to see
Previous Call Grade
F
Q2 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
32
2017–2024
Avg Candor
6.2/9
evasion 4.1/9
Evasive ManagementCritic AmmunitionCutting HeadcountReads RehearsedQuestion Left Hanging

Call-by-call analysis

🔒 Q3 2024 earnings call 2024-11-06 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor ■/9
Specificity ■/9
Evasion ■/9
Stress ■/9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q3 2024 call grade is ready
The full 37-point AI read of ABUS's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

F Q2 2024 earnings call 2024-08-01 move ±9.7%

Management gave no formal guidance. The delivery was frequently evasive.

Headcount: cuttingCapex: decreasing 4 analysts · 9 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsed
Candor 6/9
Specificity 6/9
Evasion 6/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 4/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q1 2024 earnings call 2024-05-02 move ±9.2%

Management held guidance steady. The delivery was rich in specifics.

Guidance: maintained 5 analysts · 16 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsed
Candor 6/9
Specificity 7/9
Evasion 5/9
Confidence 7/9
Uncertainty 5/9
Promotion 6/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q4 2023 earnings call 2024-02-29 move ±8.8%

Management gave no formal guidance.

Headcount: cuttingCapex: decreasing 5 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedFounder-ledDirection beats results
Candor 6/9
Specificity 6/9
Evasion 4/9
Confidence 6/9
Uncertainty 5/9
Promotion 4/9
Stress 2/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank
2 more research questions answered NO
NO Answers go deeper than the script
NO Demand off the charts

D Q3 2023 earnings call 2023-11-07 move ±10%

Management held guidance steady. The delivery was unusually candid.

Guidance: maintainedHeadcount: cuttingCapex: decreasing 4 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritableDirection beats results
Candor 7/9
Specificity 6/9
Evasion 3/9
Confidence 7/9
Uncertainty 5/9
Promotion 5/9
Stress 3/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

F Q2 2023 earnings call 2023-08-03 move ±10.4%

Management held guidance steady. The delivery was frequently evasive, promotional in tone.

Guidance: maintained 4 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 6/9
Evasion 6/9
Confidence 7/9
Uncertainty 6/9
Promotion 7/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
NO Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
YES Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

F Q1 2023 earnings call 2023-05-04 move ±11.4%

Management lowered guidance. The delivery was unusually candid, rich in specifics.

Guidance: lowered 3 analysts · 8 questions
⚑ Critic ammunition⚑ Question left hanging⚑ Reads rehearsed
Candor 7/9
Specificity 7/9
Evasion 4/9
Confidence 6/9
Uncertainty 6/9
Promotion 5/9
Stress 3/9
Complexity 7/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
NO Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q4 2022 earnings call 2023-03-02 move ±9.6%

Management gave no formal guidance. The delivery was unusually candid.

5 analysts · 14 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedDirection beats results
Candor 7/9
Specificity 6/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 8/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q3 2022 2022-11-09 D maintainedunclearunclear 6/9 5/9
Q2 2022 2022-08-04 D maintainedunclearunclear 6/9 4/9
Q1 2022 2022-05-05 D maintainedunclearunclear 7/9 4/9
Q4 2021 2022-03-03 D maintainedunclearunclear 6/9 5/9
Q3 2021 2021-11-04 F noneunclearunclear 6/9 5/9
Q2 2021 2021-08-05 D noneunclearunclear 6/9 4/9
Q1 2021 2021-05-05 D maintainedunclearunclear 6/9 4/9
Q4 2020 2021-03-04 D maintainedunclearunclear 7/9 5/9
Q3 2020 2020-11-05 F noneunclearunclear 5/9 5/9
Q2 2020 2020-08-07 D raisedunclearunclear 6/9 5/9
Q1 2020 2020-05-11 D maintainedunclearunclear 5/9 4/9
Q4 2019 2020-03-05 D maintainedunclearunclear 6/9 2/9
Q3 2019 2019-11-06 D noneunclearunclear 7/9 4/9
Q2 2019 2019-08-05 D maintainedunclearunclear 6/9 3/9
Q1 2019 2019-05-06 F noneunclearunclear 6/9 5/9
Q4 2018 2019-03-07 C maintainedunclearunclear 7/9 3/9
Q3 2018 2018-11-07 F maintainedunclearunclear 5/9 7/9
Q2 2018 2018-08-03 D maintainedunclearcontracting 6/9 3/9
Q1 2018 2018-05-06 D noneunclearcontracting 6/9 4/9
Q4 2017 2018-03-14 D noneunclearcontracting 6/9 3/9
Q3 2017 2017-11-05 C+ nonestablestable 6/9 1/9
Q2 2017 2017-08-04 C noneunclearcontracting 7/9 2/9
Q1 2017 2017-05-04 D noneunclearcontracting 6/9 3/9
Mar 2017 2017-03-21 F noneunclearunclear 6/9 4/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAMC · Altisource Asset ManagemAAON · AAON, Inc.AASZF · Atlantic Sapphire ASAAAT · American Assets Trust, IABCD · Cambium Learning Group'sABCO · The Advisory Board

← ABTX   All “A” companies    ABX →

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.